Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TransMedics Group (TMDX)

TransMedics Q2 revenue up 21% to $189.9 million; net income $14.7 million

Mixed Impact 4 of 5 earnings Written later

TransMedics reported second quarter 2026 revenue of $189.9 million, up 21% from a year earlier. Income from operations fell to $23.7 million from $36.6 million, and diluted earnings per share fell to $0.41 from $0.92, as operating expenses rose to $89.5 million from $60.0 million. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, which excludes PAD Aviation.

Key points

  • Q2 2026 revenue was $189.9 million, up 21% from $157.4 million; product revenue was $111.2 million and service revenue was $78.8 million.
  • Income from operations was $23.7 million versus $36.6 million, and diluted EPS was $0.41 versus $0.92 in Q2 2025.
  • Full-year 2026 revenue guidance low end raised; range is now $737 million to $757 million, up from $727 million to $757 million.
  • Operating expenses were $89.5 million, driven by planned investment in OCS Kidney, Gen 3.0 and clinical programs; cash was $472.7 million as of June 30, 2026.

The filing

CompanyTransMedics Group (TMDX)
Form8-K, current report
Filed with the SECAug 4, 2026, 4:05 PM ET
Accession number0001193125-26-332767

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.